152 related articles for article (PubMed ID: 36574540)
21. Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors.
Terakami T; Nagaya S; Hayashi K; Furusho H; Fujino N; Kato T; Asakura H; Morishita E
J Atheroscler Thromb; 2022 Jul; 29(7):1059-1068. PubMed ID: 34334529
[TBL] [Abstract][Full Text] [Related]
22. Simple method for removing DOACs from plasma samples.
Exner T; Michalopoulos N; Pearce J; Xavier R; Ahuja M
Thromb Res; 2018 Mar; 163():117-122. PubMed ID: 29407622
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
[TBL] [Abstract][Full Text] [Related]
24. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
25. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
[TBL] [Abstract][Full Text] [Related]
26. Application of Activators Ecarin and Factor Xa in Thrombelastography for Measurement of Anticoagulant Effect of Direct Oral Anticoagulants Using TEG 5000.
Artang R; Brod C; Nielsen JD
Semin Thromb Hemost; 2022 Oct; 48(7):808-813. PubMed ID: 36174600
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the DOAC Dipstick Test on Urine Samples With Chromogenic Substrate Methods on Plasma Samples in Outpatients Treated With Direct Oral Anticoagulants.
Papageorgiou L; Hetjens S; Fareed J; Auge S; Tredler L; Harenberg J; Weiss C; Elalamy I; Gerotziafas GT
Clin Appl Thromb Hemost; 2023; 29():10760296231179684. PubMed ID: 37278029
[TBL] [Abstract][Full Text] [Related]
28. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
Platton S; Hunt C
Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
[TBL] [Abstract][Full Text] [Related]
29. An assay to measure levels of factor Xa inhibitors in blood and plasma.
Kim PY; Di Giuseppantonio LR; Wu C; Douketis JD; Gross PL
J Thromb Haemost; 2019 Jul; 17(7):1153-1159. PubMed ID: 30985986
[TBL] [Abstract][Full Text] [Related]
30. Measurement and reversal of the direct oral anticoagulants.
Samuelson BT; Cuker A
Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests.
Favresse J; Lardinois B; Sabor L; Devalet B; Vandepapeliere J; Braibant M; Lessire S; Chatelain B; Jacqmin H; Douxfils J; Mullier F
TH Open; 2018 Apr; 2(2):e202-e209. PubMed ID: 31249943
[TBL] [Abstract][Full Text] [Related]
32. Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants.
Exner T; Ahuja M; Ellwood L
Clin Chem Lab Med; 2019 Apr; 57(5):690-696. PubMed ID: 30427777
[TBL] [Abstract][Full Text] [Related]
33. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
[TBL] [Abstract][Full Text] [Related]
34. Screening test for direct oral anticoagulants with the dilute Russell viper venom time.
Pratt J; Crispin P
Eur J Haematol; 2018 Jun; 100(6):567-574. PubMed ID: 29486103
[TBL] [Abstract][Full Text] [Related]
35. Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays.
Skaugen JM; Sayre C; Hassett AC; Chibisov I; Bontempo F; Meyer MP; Seheult JN
Am J Clin Pathol; 2022 Mar; 157(3):457-469. PubMed ID: 34698336
[TBL] [Abstract][Full Text] [Related]
36. DTI/DXI interferences with global coagulation tests in emergency hospital admissions - Results of the prospective Dresden NOAC Registry (NCT01588119).
Wunder L; Tittl L; Marten S; Beyer-Westendorf J
Thromb Res; 2019 Oct; 182():101-109. PubMed ID: 31476483
[TBL] [Abstract][Full Text] [Related]
37. Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay.
Artang R; Anderson M; Riley P; Nielsen JD
Res Pract Thromb Haemost; 2017 Oct; 1(2):194-201. PubMed ID: 30046690
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.
Nakazaki M; Oka S; Magota H; Kiyose R; Onodera R; Ukai R; Kataoka-Sasaki Y; Sasaki M; Honmou O
J Stroke Cerebrovasc Dis; 2022 Jul; 31(7):106520. PubMed ID: 35523052
[TBL] [Abstract][Full Text] [Related]
39. An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants.
Sennesael AL; Exner T; Chatelain B; Lessire S; Larock AS; Vancraeynest C; Pochet L; Dogné JM; Spinewine A; Mullier F; Douxfils J
Thromb Res; 2017 Sep; 157():29-37. PubMed ID: 28686914
[TBL] [Abstract][Full Text] [Related]
40. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jacquemin M; Jochmans K; Mullier F; Wijns W; China B; Vernelen K; Soumali MR
Int J Lab Hematol; 2017 Aug; 39(4):402-408. PubMed ID: 28304137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
